NeuroSense Therapeutics Ltd. Logo

NeuroSense Therapeutics Ltd.

A late-clinical stage company developing drugs for neurodegenerative diseases like ALS.

NRSN | US

Overview

Corporate Details

ISIN(s):
IL0011809592 (+1 more)
LEI:
Country:
United States of America
Address:
11 HAMENOFIM ST., 4672562 HERZLIYA

Description

NeuroSense Therapeutics Ltd. is a late-clinical stage drug development company focused on discovering and developing treatments for severe neurodegenerative diseases, with a primary focus on amyotrophic lateral sclerosis (ALS). The company's strategy is to create combined therapies that target multiple pertinent mechanisms involved in these complex conditions. Its lead drug candidate, PrimeC, is a unique fixed-dose combination of ciprofloxacin and celecoxib. Following a successful Phase 2b clinical trial (PARADIGM) that demonstrated a significant impact on slowing disease progression, NeuroSense is advancing PrimeC into a pivotal Phase 3 study. PrimeC has received Orphan Drug Designation from the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA). The company is also exploring therapies for other neurodegenerative diseases.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
No filings match the current criteria.

Automate Your Workflow. Get a real-time feed of all NeuroSense Therapeutics Ltd. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for NeuroSense Therapeutics Ltd.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for NeuroSense Therapeutics Ltd. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

DAEWOONG PHARMA Logo
Develops and manufactures drugs, biologics, and active pharmaceutical ingredients.
South Korea
069620
DAIICHI SANKYO COMPANY, LIMITED Logo
A global healthcare company that researches and develops novel pharmaceutical solutions.
Japan
4568
Daito Pharmaceutical Co., Ltd. Logo
Integrated manufacturer of APIs and finished drugs for generic and OTC markets.
Japan
4577
Dare Bioscience, Inc. Logo
A clinical-stage biopharmaceutical company advancing innovative products for women's health.
United States of America
DARE
Day One Biopharmaceuticals, Inc. Logo
Commercial-stage company developing targeted cancer therapies, focusing on pediatrics.
United States of America
DAWN
DBV Technologies Logo
Develops epicutaneous immunotherapy (EPIT) patch technology for food allergies.
France
DBV
DBV Technologies S.A. Logo
A clinical-stage company developing epicutaneous immunotherapy for food allergies.
United States of America
DBVT
D&D Pharmatech Inc. Logo
Clinical-stage biopharma developing GLP-1 therapies for metabolic and neurodegenerative diseases.
South Korea
347850
Dechra Pharmaceuticals PLC Logo
A global specialist in veterinary pharmaceuticals and related products.
United Kingdom
DPH
DELCATH SYSTEMS, INC. Logo
Interventional oncology company treating liver cancers with targeted chemotherapy.
United States of America
DCTH

Report Sent!

Thank you. We will check the data and update it shortly.

Talk to a Data Expert

Have a question? We'll get back to you promptly.